Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2002

View Archived Issues

Overview of DOV Pharmaceutical R&D development

Potential new applications of topiramate discussed at the CINP congress

Boehringer Ingelheim presents FAPalpha-labile prodrugs of antitumor compounds

Aventis Pasteur introduces next-generation Daptacel vaccine

Crucell licenses cell line to Korean company for HBV vaccine development

Decitabine elevates fetal hemoglobin in all sickle cell anemia patients

SSR-181507: putative atypical antipsychotic with anxiolytic/antidepressant-like properties

First clinical findings reported for inhaled NCX-950

First market approval granted in Japan for Iressa

Neuroprotective effects of immunophilin ligands

Mechanism of iroxanadine-induced cardioprotective effects

Medivir and Genzyme disclose novel cathepsin S inhibitors

New dopamine D3 antagonists identified at GSK

Alpha5-selective GABA-A receptor modulators and their use in AD

New glucose uptake activators described in Ishihara Sangyo patent

Takeda claims imidazole-based inhibitors of steroid 17-alpha-hydroxylase/17,20 lyase

BMS describes aP2 inhibitors for use in diabetes and related disorders

Potential atheroprotective effects discovered for the antiestrogen ICI-182780

Improvement in perfusion in rats with peripheral ischemia treated with 5-HT1B/5-HT2A antagonist

Effects of EGIS-7229 on hemodynamics and electrophysiological parameters in dogs

Another launch for human choriogonadotropin alfa

Prous Science webcasts over 20 hours of official sessions of the 14th International AIDS Conference

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.